ALK alteration is a frequent event in aggressive breast cancers

Breast Cancer Research

Table 3 Correlation of ALK FISH with clinicopathologic parameters in breast cancer

	Total		Amplified		Non-amplified		P value
	N	%	N	%	N	%	P value
Total number of cases	980		130	13.3	850	86.7
Age groups
<50	666	68.0	85	12.8	581	87.2	0.5018
≥50	314	32.0	45	14.3	269	85.7
Lymph nodes
N0	305	33.1	38	12.5	267	87.5	0.2010
N1	295	32.1	47	15.9	248	84.1
N2	192	20.8	25	13.0	167	87.0
N3	128	13.9	11	8.6	117	91.4
Metastasis
M0	789	89.7	111	14.1	678	85.9	0.5986
M1	91	10.3	11	12.1	80	87.9
Tumor stage
I	77	9.0	9	11.7	68	88.3	0.7588
II	374	43.8	57	15.2	317	84.8
III	311	36.5	42	13.5	269	86.5
IV	91	10.7	11	12.1	80	87.9
Histologic grade
Well differentiated	74	7.6	7	9.5	67	90.5	0.3393
Moderately differentiated	498	51.4	62	12.4	436	87.6
Poorly differentiated	397	41.0	59	14.9	338	85.1
Histology
Infiltrating ductal	896	94.0	124	13.8	772	86.2	0.0194
Infiltrating lobular	44	4.6	1	2.3	43	97.7
Mucinous	13	1.4	3	23.1	10	76.9
Recurrence
Yes	257	29.7	42	16.3	215	83.7	0.1569
No	308	70.3	77	12.7	531	87.3
ER*
Negative	332	33.9	48	14.5	284	85.5	0.4388
Positive	647	66.1	82	12.6	565	87.4
PR*
Negative	408	41.9	58	14.2	350	75.8	0.4010
Positive	566	58.1	70	12.4	496	87.6
Triple-negative*
Yes	141	14.5	16	11.3	125	88.7	0.4848
No	832	85.5	112	13.5	720	86.5
HER2 FISH*
Amplified	282	29.5	48	17.0	234	83.0	0.0418
Normal/gain	675	70.5	81	12.0	594	88.0
ALK IHC*
Present	345	36.4	61	17.7	284	82.3	0.0031
Absent	602	63.6	65	10.8	537	89.2
Ki-67 IHC
High	825	86.3	117	14.2	708	85.8	0.0569
Low	131	13.7	11	8.4	120	91.6
p-AKT
Positive	210	22.4	31	14.8	179	85.2	0.4232
Negative	729	77.6	92	12.6	637	87.4
Molecular subtype
HR+Her2-	461	47.2	58	12.6	403	87.4	0.6418
HR+Her2+	238	24.4	33	13.9	205	86.1
TNBC	141	14.4	16	11.4	125	88.6
HR-Her2+	139	13.9	22	16.2	114	83.8
Survival
OS 5 years				77.3		80.3	0.3303

ALK anaplastic lymphoma kinase, FISH fluorescence in situ hybridization, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, IHC immunohistochemistry, HR hormone receptor, TNBC triple-negative breast cancer, OS overall survival
*Data was not available (NA) for some cases: Age (NA = 27), Lymph nodes (NA = 72), Metastasis (NA = 100), Stage (NA = 144), Grade (NA = 53), Histology (NA = 27), ER (NA = 1), PR (NA = 6),Triple-negative (NA = 7), HER-2 FISH (NA = 23), ALK FISH (NA = 33), Ki-67 (NA = 24)

ISSN: 1465-542X